Our Clinical Trials - Amgen Oncology

1 OncologyOur Clinical TrialsAMG 780 (angiopoietin inhibitor) Research Area DescriptionPhaseStatusNCT/ Amgen ID*Solid TumorsAMG 780 First-In-Human Study in Adult Subjects with Advanced Solid Tumors101137552 20070879 Trebananib (AMG 386) (angiopoietin inhibitor) Research Area DescriptionPhaseStatusNCT/ Amgen ID*BreastTrebananib With Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in HER2-Positive1b00807859 20062042 BreastTrebananib Plus Paclitaxel With or Without Bevacizumab as First-Line in HER2-Negative200511459 20060341 ColorectalTrebananib in Combination With FOLFIRI200752570 20070307 Gastric, EsophagealTrebananib in Combination With Cisplatin & Capecitabine200583674 20060439 HepaticFirst-line Therapy of Trebananib in Combination With Sorafenib200872014 20080580 NSCLCT rebananib with Pemetrexed and Carboplatin in NSCLC1b/201666977 20101128 OvarianOpen-Label First-line Therapy of Trebananib With Paclitaxel and Carboplatin1b01253681 20090155 OvarianTrebananib in Combination With Pegylated Liposomal Doxorubicin or Topotecan1b00770536 20070182 OvarianTRINOVA-1: Trebananib in Combination With Paclitaxel in Recurrent Ovarian Cancer301204749 20090508 OvarianTRINOVA-3.

2 Trebananib in Combination With Paclitaxel/Carboplatin in First-Line Therapy301493505 20101129 RenalTrebananib in Combination With Sunitinib200853372 20080579 Solid TumorsTrebananib Pharmacokinetics in Cancer Subjects With Normal and Impaired Renal Function10133194120090277 Solid TumorsTrebananib With Either Motesanib, Bevacizumab, Sorafenib, or Sunitinib1b00861419 20050170 ANGIOGENESISANTIBODY DRUG CONJUGATE, continuedActive, not recruitingActive, recruitingAMG 172 (antibody drug conjugate) Research Area DescriptionPhaseStatusNCT/ Amgen ID*RenalFirst-in-Human Study of AMG 172 in Patients with Kidney Cancer10149782120090515 ANTIBODY DRUG CONJUGATEAMG 900 (pan-Aurora kinase inhibitor) Research Area DescriptionPhaseStatusNCT/ Amgen ID*LeukemiaAMG 900 in Adult Subjects With Acute Leukemias and Related Disorders101380756 20101351 Solid TumorsAMG 900 First-In-Human Study in AdultSubjects With Advanced Solid Tumors10085837720080016 CELL CYCLED enosumab (RANK ligand inhibitor) Research Area DescriptionPhaseStatusNCT/ Amgen ID*BreastDenosumab Study in Adjuvant Breast Cancer (D-CARE)

3 30107715420060359 BreastPlacebo-Controlled Study of Denosumab in Patients Receiving Aromatase Inhibitor Therapy300556374 20050209 Giant Cell TumorDenosumab in Recurrent or Unresectable Giant Cell Tumor of the Bone200680992 20062004 Multiple MyelomaDenosumab Compared to Zoledronic Acid for Treatment of Bone Disease in Multiple Myeloma301345019 20090482 ProstateDenosumab Study on Lens Opacifications in Non-Metastatic Patients on ADT300925600 20080560 Solid Tumors and Multiple MyelomaDenosumab in the Treatment of Hypercalcemia of Malignancy200896454 20070315 BONE METASTASES AND METABOLISMAMG 595 (anti-EGFRvIII) Research Area DescriptionPhaseStatusNCT/ Amgen ID*GliomaFirst-In-Human Study of AMG 59510147500620090505 GROWTH REGULATIONR ilotumumab (HGF/SF inhibitor) Research Area DescriptionPhaseStatusNCT/ Amgen ID*ColorectalRilotumumab or Ganitumab in Combination With Panitumumab1b/200788957 20060447 Gastric, EsophagealRilotumumab in Combination With Epirubicin, Cisplatin, and Capecitabine1b/200719550 20060317 Gastric, EsophagealRILOMET-1.

4 Rilotumumab with ECX in First-Line Treatment for MET-Positive Gastric, Lower Esophageal, or GEJ Adenocarcinoma30169707220070622 ProstateRilotumumab in Combination With Mitoxantrone and Prednisone1b/200770848 20070611 SCLCR ilotumumab or Ganitumab in Combination With Cisplatin or Carboplatin, and Etoposide1b/200791154 20060534 AMG 319 (PI3K inhibitor) Research Area DescriptionPhaseStatusNCT/ Amgen ID*LymphomaAMG 319 First-in-Human Study in Adult Subjects with Lymphoid Malignancy10130002620101262 AMG 337 (MET inhibitor) Research Area DescriptionPhaseStatusNCT/ Amgen ID*Solid TumorsFirst-in-Human Study of AMG 33710125370720101132 Ganitumab (IGF1R antagonist) Research Area DescriptionPhaseStatusNCT/ Amgen ID*ColorectalPanitumumab Plus Irinotecan Followed by Panitumumab Plus Ganitumab200891930 20070820 SCLCG anitumab or Rilotumumab (AMG 102) in Combination With Cisplatin or Carboplatin, and Etoposide1b/200791154 20060534 HEMATOPOIESISD arbepoetin alfa (erythropoiesis-stimulating agent) Research Area DescriptionPhaseStatusNCT/ Amgen ID*MDSD arbepoetin alfa for the Treatment of Anemic Subjects With Low or Intermediate-1 Risk MDS30136214020090160 NSCLCI mpact of Darbepoetin alfa on Survival in Anemic Subjects Receiving Chemotherapy300858364 20070782 GROWTH REGULATION, continuedPanitumumab (EGFR inhibitor)

5 Research Area DescriptionPhaseStatusNCT/ Amgen ID*ColorectalSPIRITT: Second-line Therapy of Panitumumab or Bevacizumab in Combination With FOLFIRI200418938 20060141 ColorectalPEAK: First-line Therapy of Panitumumab or Bevacizumab in Combination With mFOLFOX620081978020070509 ColorectalPanitumumab Plus Irinotecan Followed by Panitumumab Plus Ganitumab (AMG 479)200891930 20070820 ColorectalPanitumumab With Best Supportive Care (BSC) vs BSC Alone301412957 20100007 ColorectalASPECCT: Panitumumab Efficacy and Safety Compared to Cetuximab in Subjects With WT KRAS mCRC301001377 20080763 Head & NeckPRISM: Second-line Therapy With Panitumumab200446446 20062088 Head & NeckCONCERT2: Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy 200547157 20062079 Head & NeckPARTNER.

6 Cisplatin and Docetaxel With or Without Panitumumab20045477920050236 Head & NeckPharmacokinetic Study of Chemotherapy With or Without Panitumumab20075644420080008 Panitumumab (EGFR inhibitor), continued Research Area DescriptionPhaseStatusNCT/ Amgen ID*Solid TumorsPanitumumab Pediatric Study100658658 20050252 GROWTH REGULATION, continuedOther Clinical Trials Research Area DescriptionPhaseStatusNCT/ Amgen ID*FN Study to Investigate the Relationship Between Physician-Assessed Febrile Neutropenia (FN) Risk Probability Score and Prediction Tool FN Risk Probability Score for Patients With Non-Myeloid Malignancies n/a 20090344 Romiplostim (thrombopoiesis stimulator) Research Area DescriptionPhaseStatusNCT/ Amgen ID*ITPI nterventional Study in Adult Subjects with ITP Receiving Romiplostim201143038 20080435 ITPLong-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With ITP301071954 20090340 ITPS afety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects30144441720080279 MDSP lacebo-Controlled Study of Romiplostim(All subjects have been removed from treatment and are being followed for observation)20061452320060198 AMG 208 (MET inhibitor) Research Area DescriptionPhaseStatusNCT/ Amgen ID*Solid TumorsFirst-In-Human Study of AMG 208100813384 20080895 Active, not recruitingActive, recruitingPegfilgrastim (granulocyte colony-stimulating factor)

7 Research Area DescriptionPhaseStatusNCT/ Amgen ID*BreastNOLAN: The Effect of Prophylactic Naproxen or Loratidine on Bone Pain with Chemotherapy and Pegfilgrastim20171200920110147 Breast RIAN: The Effect of Patient Education on Reported Bone Pain with Chemotherapy and Pegfilgrastim2 20110148 Colorectal PAVES: Placebo-Controlled Study of Pegfilgrastim With Bevacizumab and Either FOLFOX or FOLFIRI30091117020080259 Amgen aspires to be the best human therapeutics company. Amgen is committed to developing new therapies to treat serious illnesses a long and careful process. Among the most important steps in this process are the Clinical Trials , where people volunteer to receive an experimental new drug or procedure and be observed for its effects.

8 At Amgen , we apply four guiding principles to our research and development efforts. The first is to focus on grievous illness. Given the difficulty of successfully developing a new therapy, we focus our efforts on developing therapies to help patients suffering from the greatest unmet medical needs. Our second guiding principle is to be modality independent. Small molecules and biotherapeutics (biologics) each have unique and inherent advantages and disadvantages. Our modality independent approach allows us to leverage the advantageous aspects of a particular approach that are best suited to interdict a disease. Our third major emphasis is to study disease in patients.

9 While it is significantly more complicated to study disease in humans, we believe that this is the only way to successfully develop human therapeutics. Our fourth guiding principle, seamless integration, informs everything we do. There are important insights that come to basic research and Clinical development from understanding the medical marketplace, and vice versa. Aligning our priorities across these functions ensures that we develop potential therapeutics in a manner that will address unmet medical needs and meet the changing demands of the s Research and Development VisionIMMUNOTHERAPYTUMOR ASSOCIATED MACROPHAGESAMG 820 (c-fms inhibitor) Research Area DescriptionPhaseStatusNCT/ Amgen ID*Solid TumorsFirst-in-Human Study of AMG 820101444404 20060347 Talimogene Laherparepvec (oncolytic immunotherapy) Research Area DescriptionPhaseStatusNCT/ Amgen ID*MelanomaOPTiM : Talimogene Laherparepvec Compared to GM-CSF in Unresectable Melanoma300769704 Information as of 11/09/12.

10 Statements are based on the company s current beliefs and Amgen disclaims any duty to update. For more information about Amgen and its business, including risks and uncertainties, please refer to Amgen s filings with the SEC. Products under investigational study have not been approved by the FDA for the use under investigation. This information is provided only for purposes of providing general information on Clinical Trials and stages of development on the select candidates identified. This information should not be construed as a recommendation for use of any product for unapproved uses.*For more detailed information about the trial, visit or Previously referred to as OncoVEXGM-CSF OPTiM = OncoVEXGM-CSF Pivotal Trial In (bispecific T cell engager antibody)